Clinical Trial: NCT02143466
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-10-21 |
Study Overview
Brief Summary
The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients with EGFR mutation positive advanced lung cancer
Official Title
A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).
Conditions
Advanced Non Small Cell Lung Cancer
Intervention / Treatment
- Drug: Part A - AZD9291 in combination with AZD6094
- Drug: Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)
- Drug: Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)
- Drug: Part A - AZD9291 in combination with intermittent selumetinib
- Drug: Part A - AZD9291 in combination with MEDI4736
- Drug: Part B - AZD9291 in combination with AZD6094
- Drug: Part B - AZD9291 in combination with selumetinib
- Drug: Part B - AZD9291 in combination with MEDI4736
- Drug: Part C - AZD6094 monotherapy (Japan only)
- Drug: Part C - AZD9291 in combination with AZD6094 (Japan only)
- Drug: Part D - AZD9291 in combination with AZD6094
Other Study ID Numbers
- D5160C00006
- 2016-004752-29
- 2016
Start Date (Actual)
2014-08-05
Primary Completion Date (Actual)
2020-03-04
Study Completion Date (Estimated)
2026-12-31
Enrollment (Actual)
344
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-10-21 |
Study Overview
Brief Summary
The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients with EGFR mutation positive advanced lung cancer
Official Title
A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).
Conditions
Advanced Non Small Cell Lung Cancer
Intervention / Treatment
- Drug: Part A - AZD9291 in combination with AZD6094
- Drug: Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)
- Drug: Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)
- Drug: Part A - AZD9291 in combination with intermittent selumetinib
- Drug: Part A - AZD9291 in combination with MEDI4736
- Drug: Part B - AZD9291 in combination with AZD6094
- Drug: Part B - AZD9291 in combination with selumetinib
- Drug: Part B - AZD9291 in combination with MEDI4736
- Drug: Part C - AZD6094 monotherapy (Japan only)
- Drug: Part C - AZD9291 in combination with AZD6094 (Japan only)
- Drug: Part D - AZD9291 in combination with AZD6094
Other Study ID Numbers
- D5160C00006
- 2016-004752-29
- 2016
Start Date (Actual)
2014-08-05
Primary Completion Date (Actual)
2020-03-04
Study Completion Date (Estimated)
2026-12-31
Enrollment (Actual)
344
Study Type
Interventional
Phase
Phase 1